A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial

OBJECTIVES: The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolastin®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma levels of i...

Descripción completa

Detalles Bibliográficos
Autores principales: McEvoy, Natalie L., Clarke, Jennifer L., Mc Elvaney, Oliver J., Mc Elvaney, Oisin F., Boland, Fiona, Hyland, Deirdre, Geoghegan, Pierce, Donnelly, Karen, Friel, Oisin, Cullen, Ailbhe, Collins, Ann M., Fraughen, Daniel, Martin-Loeches, Ignacio, Hennessy, Martina, Laffey, John G., Mc Elvaney, Noel G., Curley, Gerard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054126/
https://www.ncbi.nlm.nih.gov/pubmed/33874981
http://dx.doi.org/10.1186/s13063-021-05254-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054126/
https://www.ncbi.nlm.nih.gov/pubmed/33874981
http://dx.doi.org/10.1186/s13063-021-05254-0

Ejemplares similares